Immunic AG, a young biotech company based in IZB in Martinsried near Munich, was able to recently completed first investment round to a total of 21.7 million euros.
IBG Risikokapitalfonds II GmbH & Co. KG has joined the international investor consortium as a new investor, led by the Dutch lead investor LSP and the co-lead investor LifeCarePartners.
The Immunic AG was founded in April 2016 with the goal of bringing targeted pharmaceutical development projects to clinical proof of concept. The company develops products in the field of chronic inflammatory and autoimmune diseases, such as ulcerative colitis, Crohn's disease, and psoriasis.
Investment round expanded: “This step is particularly important”
Dr. Daniel Vitt, Immunics CEO and Spokesperson, says:
"We are very pleased that IBG has expanded our investor base, allowing us to raise an additional four million euros in equity financing. This step is particularly important for the rapid further development of our two lead products (...) for the treatment of autoimmune diseases with high medical need."
“Outstanding therapeutic products”
“We are convinced that Immunic’s outstanding therapeutic products, managed by an experienced development team, will sustainably improve the treatment options for chronic inflammatory diseases,”
says Dr. Angelika Vlachou, Investment Manager at bmp.
